PIK3CA and breast carcinoma: RNMT is a promising therapeutic target in PIK3CA (phosphatidylinositol-4,5- bisphosphate 3-kinase catalytic subunit alpha gene) mutant breast cancer, as PIK3CA mutations in breast cells depend on RNMT (mRNA cap methylation) for their survival and proliferation13.